Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hopital Foch
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COPD with dyspnoea with Medical Research Council scale (MRC) \>1,
No exacerbation for 6 weeks
No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours before the respiratory evaluation and the test of reversibility.
Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1 hour the day of the visit
Having given a written consent
You may not be if
Patient Under 18
Other respiratory illness
Clinically significant left cardiac failure
Obesity with BMI \> 35 kg / m2)
Unable to perform respiratory evaluations
Contraindication to the salbutamol or to the ipratropium bromide or to one of its components
Pregnant or breast-feeding woman
Unable to agree
No social security scheme
Clareo Health | Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea
